LONDON – Anglo-Swedish pharmaceutical company AstraZeneca PLC warned over expiring patents on its medicines as the company announced a 37 per cent fall in full-year net profit.
AstraZeneca said that its net profit fell to $6.3 billion in the year ended Dec. 31, compared with nearly $10 billion in 2011. The company blamed the loss of exclusivity on several big-name drugs for a drop in revenue to $28 billion from $33.6 billion a year earlier.
Get weekly money news
In one example, U.S. revenue fell 21 per cent, largely due to competition from generic versions of AstraZeneca’s anti-depression medication Seroquel IR.
- Alberta tweaks carbon capture incentive program to allow grants during construction
- ‘Cash is king’: Why money is a popular holiday present for many Canadians
- Rancher says Alberta well cleanup fund a positive step — but litany of concerns remain
- What makes the Anthropic IPO so significant, and what is the ‘god share’?
Chief executive Pascal Soriot said Thursday the company’s 2012 performance “reflects a period of significant patent expiry and tough market conditions.”
He said the company’s new leadership team would focus on the company’s brands and product pipeline.
Comments
Want to discuss? Please read our Commenting Policy first.